Linden Thomas Advisory Services LLC Has $2.29 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Linden Thomas Advisory Services LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,607 shares of the biopharmaceutical company’s stock after acquiring an additional 136 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $2,290,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ronald Blue Trust Inc. grew its position in Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 12 shares during the last quarter. IFP Advisors Inc grew its position in Regeneron Pharmaceuticals by 9.7% during the 3rd quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 39 shares during the last quarter. Ritholtz Wealth Management grew its position in Regeneron Pharmaceuticals by 18.3% during the 3rd quarter. Ritholtz Wealth Management now owns 510 shares of the biopharmaceutical company’s stock worth $420,000 after acquiring an additional 79 shares during the last quarter. Global Retirement Partners LLC grew its position in Regeneron Pharmaceuticals by 67.1% during the 3rd quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 100 shares during the last quarter. Finally, Park Place Capital Corp grew its position in Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 15 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the transaction, the director now owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the transaction, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Up 0.9 %

Shares of REGN stock traded up $8.00 during mid-day trading on Tuesday, reaching $908.16. The stock had a trading volume of 188,783 shares, compared to its average volume of 489,175. The stock’s 50-day moving average price is $952.07 and its two-hundred day moving average price is $892.70. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The firm has a market capitalization of $99.68 billion, a PE ratio of 25.90, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company earned $10.96 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on REGN shares. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective for the company. Finally, Bank of America upped their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $976.41.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.